Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

about

Association of Smoking, Alcohol Use, and Betel Quid Chewing with Epigenetic Aberrations in Cancers.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

P2860

Q33838727-9AD16DF1-D275-4935-AE3F-76486FE3D9A0 Q49887884-114F51FB-E147-464D-96C8-5DE3124B44DD

P2860

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

Item

http://www.wikidata.org/entity/Q38771802

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Combination of panobinostat wi ...... s imatinib-resistant CML cells

@en

type

Item

label

Combination of panobinostat wi ...... s imatinib-resistant CML cells

@en

prefLabel

Combination of panobinostat wi ...... s imatinib-resistant CML cells

@en

P1476

Combination of panobinostat wi ...... s imatinib-resistant CML cells

@en

P2093

Akira Yoshida

http://www.w3.org/2001/XMLSchema#string

Eiju Negoro

http://www.w3.org/2001/XMLSchema#string

Kanako Uzui

http://www.w3.org/2001/XMLSchema#string

Koji Morinaga

http://www.w3.org/2001/XMLSchema#string

Naoko Hosono

http://www.w3.org/2001/XMLSchema#string

Rie Nishi

http://www.w3.org/2001/XMLSchema#string

Shinya Kimura

http://www.w3.org/2001/XMLSchema#string

Taira Maekawa

http://www.w3.org/2001/XMLSchema#string

Takahiro Yamauchi

http://www.w3.org/2001/XMLSchema#string

Takanori Ueda

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

P304

1029-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12965

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27166836

http://www.w3.org/2001/XMLSchema#string

P932

4946706

http://www.w3.org/2001/XMLSchema#string

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

about

P2860

P2860

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932